🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Hematologic Malignancies
Clinical trial register · United States · industry-sponsored

Hematologic Malignancies Trials in the USA

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9094 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 17 Sep 2026, 08:23 UTC
9094
Studies in scope
industry-sponsored, all four open statuses
4935
Recruiting now
open to new participants
2188
Lead sponsors
across recruiting studies
Top states
California 8 Michigan 5 Florida 4 Georgia 4 Colorado 4
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Merck Sharp & Dohme LLC2 Sellas Life Sciences Group1 Pulmotect, Inc.1 Kumquat Biosciences Inc.1 Tempus AI1
State
California8 Michigan5 Florida4 Georgia4 Colorado4
All 26 states
Target enrolment
to
10 of 9094 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
Tempus Open Link for Individual Voices in Innovative Analytics Registry: Platform Protocol for Multimodal Real-World Evidence in Cancer
NCT07756034Cancer, Solid Tumor Cancer, Pediatric Acute Myeloid Leukemia, Hematologic Malignancies
Tempus AI
Observational
1,000
Illinois
2026-08
Recruiting
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
NCT07195916Solid Tumors, Hematologic Malignancies
Incyte Corporation
Phase 1
280
California, Michigan, Nebraska, New York, Tennessee, Texas
2026-01-08
Recruiting
PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)
NCT06665100Hematologic Malignancies, Hematopoietic Stem Cell Transplant (HSCT)
Pulmotect, Inc.
Phase 2
100
California, Georgia, Maryland, Massachusetts, Michigan, Minnesota, New Jersey, New York
2025-06-27
Recruiting
A Phase 1 Study of IM-1021 in Participants With Advanced Cancer
NCT06823167Solid Malignancies, Hematologic Malignancies
Immunome, Inc.
Phase 1
190
California, Colorado, Connecticut, Florida, Georgia, Iowa, Kentucky, Michigan
2025-02-26
By invitation
Follow-Up for Study Participants Treated With an Allogeneic CAR T-Cell Product
NCT06925685Hematologic Malignancies, Solid Tumors
Allogene Therapeutics
Observational
50
New York
2025-01-31
Active, closed
A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Hematologic Malignancies
NCT06645886Hematologic Malignancies, Adult
Kumquat Biosciences Inc.
Phase 1
13
California, Colorado, Florida, Michigan, North Carolina, Ohio, Tennessee, Texas
2024-12-09
Recruiting
Study to Evaluate the Pharmacokinetics and Safety of Pralatrexate in Patients With Advanced Solid Tumor or Hematological Malignancy and Either Normal Hepatic Function or Mild, Moderate, or Severe Hepatic Impairment
NCT07036133Advanced Solid Tumors, Hematologic Malignancies
Acrotech Biopharma Inc.
Phase 1
24
California, Illinois, Michigan, Ohio
2022-12-28
Recruiting
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
NCT04588922Hematologic Malignancies
Sellas Life Sciences Group
Phase 1/2
160
Alabama, Arizona, California, Florida, Georgia, Illinois, Louisiana, Massachusetts
2021-05-10
Recruiting
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
NCT04728893Hematologic Malignancies, Waldenstroms Macroglobulinaemia, Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukaemia
Merck Sharp & Dohme LLC
Phase 2
490
Arkansas, California, Colorado, Kentucky, Minnesota, New Jersey, North Dakota, Texas
2021-04-05
Recruiting
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
NCT03486873Solid Tumors, Hematologic Malignancies
Merck Sharp & Dohme LLC
Phase 3
3,500
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Hawaii
2018-08-21
Rows per page Showing 1–10 of 10
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 17 September 2026. https://priyalifescience.com/clinical-trials-usa/condition/hematologic-malignancies

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.